Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Huang, Liang  [Clear All Filters]
2014
Han Z, Wang X, Ma L, Chen L, Xiao M, Huang L, Cao Y, Bai J, Ma D, Zhou J, et al. Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer. Oncotarget. 2014.
2019
Li Y, Sun X, Liu H, Huang L, Meng G, Ding Y, Su W, Lu J, Gong S, Terstappen GC, et al. Development of Human in vitro Brain-blood Barrier Model from Induced Pluripotent Stem Cell-derived Endothelial Cells to Predict the in vivo Permeability of Drugs. Neurosci Bull. 2019.
Gao X, Wu D, Dou L, Zhang H, Huang L, Zeng J, Zhang Y, Yang C, Li H, Liu L, et al. Protective Effects of Mesenchymal Stem Cells Overexpressing Extracellular Regulating Kinase 1/2 Against Stroke in Rats. Brain Res Bull. 2019.
2020
Liu L, Liu Y, Li N, Huang R, Zheng X, Huang L, Hou S, Yuan Q. Multiple inflammatory profiles of microglia and altered neuroimages in APP/PS1 transgenic AD mice. Brain Res Bull. 2020.
2021
Cao Y, Yi X, Wang N, Wang GX, Huang L, Hong Z, Meng L, Zhou X, Wang J, Hao X, et al. CD19/CD22 CAR T cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas: Combined CAR T Cell Therapy and Transplantation. Transplant Cell Ther. 2021.
2023
Sun T, Li D, Huang L, Zhu X. Inflammatory abrasion of hematopoietic stem cells: a candidate clue for the post-CAR-T hematotoxicity?. Front Immunol. 2023;14:1141779.
An Z-Y, Wu Y-J, Hou Y, Mei H, Nong W-X, Li W-Q, Zhou H, Feng R, Shen J-P, Peng J, et al. A life-threatening bleeding prediction model for immune thrombocytopenia based on personalized machine learning: a nationwide prospective cohort study. Sci Bull (Beijing). 2023.
2024
Zhang S, Zhou X, Zhang S, Wang N, Zhang T, Zhang D, Ao Q, Cao Y, Huang L. EBV-associated lymphoproliferative disease post-CAR-T cell therapy. Front Med. 2024.
Xin X, Zhu X, Yang Y, Wang N, Wang J, Xu J, Wei J, Huang L, Zheng M, Xiao Y, et al. Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma. Cell Oncol (Dordr). 2024.
Peng Y, Huang J, Yin J, Meng F, Cao Y, Huang L, Li D, Zhang Y, Zhang D, Meng L, et al. Frontline combination of dasatinib and low-intensity chemotherapy in adults with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Rev Hematol. 2024.
Xin X, Lin L, Yang Y, Wang N, Wang J, Xu J, Wei J, Huang L, Zheng M, Xiao Y, et al. Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in. Cytotherapy. 2024.
Yang P, Cai M, Cao Y, Fan S, Tang W, Ji M, Huang L, Wang F, Zhao W, Niu T, et al. Up-front autologous stem cell transplant in peripheral T-cell lymphoma patients achieving complete response after first-line treatment: A multicentre real-world analysis. Br J Haematol. 2024.
Zhang Q, Li C, Cao Y, Wang N, Huang L, Shang Z, Wang J, Huang L, Xu J, Xiao M, et al. Upper gastrointestinal tract immune-related adverse events: Two cases of obstructive complications occurred in immune consolidation therapy after sequential chimeric antigen receptor T cell therapy with autologous hematopoietic stem cell transplantation f. Clin Case Rep. 2024;12(1):e8411.